Books Books

Fundamentals of US Regulatory Affairs, 11th Edition

Member: $147.50 Nonmember: $197.50
Fundamentals of US Regulatory Affairs, 11th Edition

>> View Table of Contents
>> Take a Look Inside (Sample Chapter)
>> Author Acknowledgments

This 11th edition of Fundamentals of US Regulatory Affairs presents information covering all lifecycle stages of regulated healthcare products. More than 50 authors contributed to the content, which is current through April 2019. The content in this edition is more detailed than in the past and includes a new chapter on the master protocol. The book is divided into eight sections:
  1. General Information
  2. Drugs
  3. Medical Devices
  4. Biologics
  5. Foods
  6. Other Product Classifications
  7. Inspection and Enforcement
  8. Resources

General chapters cover such topics as the history of US regulation, FDA meetings, user fees, regulatory strategy, healthcare fraud and abuse and traceability. Specific sections discuss product development through postmarket compliance. Other chapters address orphan drugs, foods, blood products and those derived from blood as well as tissue and cellular products. 

Who Should Use This Publication?

Fundamentals of US Regulatory Affairs is designed for regulatory professionals working on products for the US market at all levels and is a useful tool for those planning to sit for the RAC US, drug or medical device exam. Whether you’re new to the profession or a veteran, you’ll find valuable information in the carefully curated pages.

Bonus: Free E-book with Every Purchase

Receive a free e-copy of the Fundamentals of US Regulatory Affairs, 11th Edition with every purchase of the printed version. Note: The Fundamentals of US Regulatory Affairs, 11th Edition e-book is no longer available for purchase separately.

Studying for the RAC? Take a look at our RAC prep resources.

Published by RAPS © 2019. Hardcover. 752 pages. ISBN:978-1-947493-33-9.

Add Book to Cart

Discover more of what matters to you

BiologicsComplianceMedical DevicesNorth AmericaPharmaceuticals

News »